Insurance-Driven Switching and Real-World Treatment Outcomes of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study

Journal article

Peer reviewed

Yumeng T Engelking and Ali Jabbari

Journal of the American Academy of Dermatology

03/04/2026

DOI: 10.1016/j.jaad.2026.02.115

PMID: 41791515

View Online

no abstract | brief report

Treatment switching

Tofacitinib

Efficacy

JAK inhibitor

Hair regrowth

SALT score

Insurance authorization

Ritlecitinib

Treatment duration

Baricitinib

Alopecia areata

Title: Subtitle: Insurance-Driven Switching and Real-World Treatment Outcomes of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study
Creators: Yumeng T Engelking - University of Iowa
Ali Jabbari - University of Iowa
Resource Type: Journal article
Publication Details: Journal of the American Academy of Dermatology
DOI: 10.1016/j.jaad.2026.02.115
PMID: 41791515
NLM abbreviation: J Am Acad Dermatol
ISSN: 1097-6787
eISSN: 1097-6787
Publisher: Elsevier
Language: English
Electronic publication date: 03/04/2026
Academic Unit: Dermatology
Record Identifier: 9985141991702771

5 Record Views